Who is sponsoring NCT03682744?

NCT03682744 is sponsored by Sorrento Therapeutics, Inc..

What condition does NCT03682744 study?

NCT03682744 studies Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Gastric Cancer, Breast Cancer, Pancreas Cancer, Carcinoembryonic Antigen.

What drugs are being tested in NCT03682744?

Interventions: anti-CEA CAR-T cells.

What is the status of NCT03682744?

NCT03682744 is currently WITHDRAWN.

Last reviewed 2022-03-25 · How we verify

Immunotherapy for Peritoneal Carcinomatosis (IPC) - A Phase I Study of the Safety and Efficacy of Anti-CEA CAR-T Cell Intraperitoneal Infusions for Treatment of CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites

NCT03682744 Phase 1 WITHDRAWN

This is an open-label, dose-escalation, phase I trial of the safety and efficacy of anti-CEA intraperitoneal CAR-T infusions for treatment in patients with CEA-expressing adenocarcinoma peritoneal metastases or malignant ascites.

Details

Lead sponsor	Sorrento Therapeutics, Inc.
Phase	Phase 1
Status	WITHDRAWN
Start date	2018-09-13
Completion	2021-03

Conditions

Peritoneal Carcinomatosis
Peritoneal Metastases
Colorectal Cancer
Gastric Cancer
Breast Cancer
Pancreas Cancer
Carcinoembryonic Antigen

Interventions

anti-CEA CAR-T cells

Primary outcomes

Safety of Intraperitoneal CAR-T Cell Infusions as Measured by Number of Participants with Adverse Events — 16 weeks
To determine the safety and maximum tolerated dose (MTD) following intraperitoneal infusion(s) of anti-CEA CAR-T cells for inoperable CEA+ peritoneal metastases or malignant ascites.

Countries

United States